RSS Feeds
Aspirin Use and Risk for Colorectal Adenoma
- Andrew T. Chan, MD, MPH; and
- Charles S. Fuchs, MD, MPH
- From Massachusetts General Hospital, Boston, MA 02114, and Dana-Farber Cancer Institute, Boston, MA 02115.
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
IN RESPONSE:
We appreciate Dr. Scovern's request for a clarification of our results. As we described in a footnote to our Table 4, we defined short-term use of aspirin as regular intake for no more than 5 consecutive years immediately preceding a participant's endoscopy. We did not directly examine nonconsecutive years of use or 5 years of aspirin use earlier in life. Thus, it remains unknown whether intermittent or remote aspirin use reduces risk for adenoma. However, on the basis of observed experience with nonsteroidal anti-inflammatory drugs in patients with familial polyposis (1), it appears that polyps will eventually recur after discontinuation of therapy.
Andrew T. Chan, MD, MPH
Massachusetts General Hospital, Boston, MA 02114
Charles S. Fuchs, MD, MPH
Dana-Farber Cancer Institute, Boston, MA 02115
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
